The FTC claims Martin Shkreli broke his lifetime ban from the drug industry by trading stock.

TVTX · Travere Therapeutics Inc.

The AI's read

Travere’s link is that Shkreli once led its predecessor, Retrophin. The requested sale of Shkreli’s drug shares and penalties target him, not Travere. The report does not identify a Travere trade or a change in its business, so it gives no new reason to expect a change for the company.